Evidence map›Paper›PMID 39704806›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Zinc oxide fabricated by rutin as potent anti-leukemia nanostructure.

Fatemeh Azizi Alidoust, Hossein Zahmatkesh, Behnam Rasti, Hojjatolah Zamani, Mirsasan Mirpour, Amir Mirzaie

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fatemeh Azizi AlidoustDepartment of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University, Lahijan, Iran.
Hossein ZahmatkeshDepartment of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University, Lahijan, Iran.
Behnam RastiDepartment of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University, Lahijan, Iran. behnam.rasti@iau.ac.ir.
Hojjatolah ZamaniDepartment of Biology, University of Guilan, Rasht, Iran. h_zamani@guilan.ac.ir.
Mirsasan MirpourDepartment of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University, Lahijan, Iran.
Amir MirzaieDepartment of Biology, Parand Branch, Islamic Azad University, Parand, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of chronic myeloid leukemia (CML) is a significant therapeutic challenge, and exploration of novel treatment approaches is an urgent necessity. This work investigates the anticancer properties of rutin-conjugated zinc oxide nanoparticles (Rut-ZnO NPs) against CML cells. Physicochemical properties of the NPs were studied by FT-IR, FE-SEM, XRD, zeta potential, and DLS analyses. The MTT, flow cytometry, and quantitative PCR assays were utilized to evaluate cell viability, apoptosis, and Bax/Bcl-2 ratio, respectively. The ZnO-Rut NPs were amorphous with an average size of 59.50 nm, and hydrodynamic size and zeta potential were 161.7nm and -34.3 mV, respectively. The ZnO-Rut NPs showed good cytocompatibility as the viability of peripheral blood mononuclear cells remained above 85% at concentrations up to 100 μg/mL. ZnO-Rut NPs reduced the viability of K562 cells from 92 to 31% at exposure concentrations from 3.125 to 400 μg/mL. The IC

Indexed as

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMetal NanoparticlesRutinZinc OxideApoptosisbcl-2-Associated X ProteinCell SurvivalHumansK562 CellsLeukocytes, MononuclearProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanProto-Oncogene Proteins c-bcl-2RutinZinc OxideApoptosisChronic myeloid leukemiaK562 cellsRutinZinc oxide

Identifiers

PMID39704806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.